Serdemetan (JNJ-26854165)

Name: Serdemetan (JNJ-26854165)
Brand: Selleck Chemicals
SKU: S1172
Rating: 5 (11 reviews)

For research use only.

Catalog No.S1172

11 publications

Serdemetan (JNJ-26854165) Chemical Structure

CAS No. 881202-45-5

Serdemetan (JNJ-26854165) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.

Selleck's Serdemetan (JNJ-26854165) has been cited by 11 publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Res, 2020, canres.3499.2019

PubMed: 33372039 ( click the link to review the publication )

Circulation, 2020, 10.1161/CIRCULATIONAHA.120.048191

PubMed: 32755395 ( click the link to review the publication )

BMC Pharmacol Toxicol, 2017, 18(1):40

PubMed: 28577368 ( click the link to review the publication )

Oncotarget, 2017, 8(5):7777-7790

PubMed: 27999193 ( click the link to review the publication )

Sci Signal, 2016, 9(448):ra98

PubMed: 27703031 ( click the link to review the publication )

Mol Ther, 2015, 23(5):857-65

PubMed: 25648263 ( click the link to review the publication )

Sci Rep, 2014, 4:4664

PubMed: 24722541 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

6 Customer Reviews

Mol Pharmacol 2014 85(3), 408-19. Serdemetan (JNJ-26854165) purchased from Selleck.

Sci Rep 2014 4, 4663. Serdemetan (JNJ-26854165) purchased from Selleck.
Sci Rep 2014 4, 4663. Serdemetan (JNJ-26854165) purchased from Selleck.

Sci Rep 2014 4, 4663. Serdemetan (JNJ-26854165) purchased from Selleck.
J Nat Med 2013 10.1007/s11418-014-0825-0. Serdemetan (JNJ-26854165) purchased from Selleck.

Curr Protoc Chem Biol 2013 5(3), 195-212. Serdemetan (JNJ-26854165) purchased from Selleck.

Purity & Quality Control

Choose Selective p53 Inhibitors

Biological Activity

Description

Targets

p53 ^[1]
(Cell-free assay)

HDM2 ^[1]
(Cell-free assay)

Mdm2 ^[2]
(Cell-free assay)

In vitro

JNJ 26854165 is a novel tryptamine derivative which activates p53 and acts as a HDM2 ubiquitin ligase antagonist. JNJ 26854165 inhibits cell growth and induces apoptosis in leukemia cell lines with IC50 values of 0.24, 0.33, 0.32 and 0.44 μM at 72 hours for OCI-AML-3, MOLM-13, NALM-6 and REH cells, respectively. In addition, JNJ 26854165 accelerates proteasome-mediated degradation of p21 and antagonizes the transcriptional induction of p21 by p53. It also induces S-phase delay and upregulates E2F1 expression in p53 mutant cells, resulting in preferential apoptosis of S-phase cells. ^[1] JNJ 26854165 is an oral Mdm2 inhibitor which can inhibit the interaction of Mdm2-p53 complex with the proteasome and increase p53 levels by binding to RING domain of Mdm2. ^[2] A recent study shows that JNJ 26854165 inhibits clonogenic survival in four human cancer cell lines: H460, A549, p53-WT-HCT116, and p53-null-HCT116. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
KU-19-19 cell	M1P3c2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MknCTY5pcWKrdHnvckBw\iCqdX3hckBMXS1zOT2xPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTN{M{[g{txO	NIXkXIRUSU6JRWK=
H4 cell	NV3KfndjT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NGPu[2NKdmirYnn0bY9vKG:oIHj1cYFvKEh2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6wOlcxPyEQvF2=	MUDTRW5ITVJ?
KGN cell	MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NEXPRWhKdmirYnn0bY9vKG:oIHj1cYFvKEuJTjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuOlIxPSEQvF2=	NWi1XpJqW0GQR1XS
786-0 cell	MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MVHJcohq[mm2aX;uJI9nKGi3bXHuJFc5Pi1yIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT63Nlk5QSEQvF2=	Mny0V2FPT0WU
769-P cell	NXq0O2Z[T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NEXXZ5hKdmirYnn0bY9vKG:oIHj1cYFvKDd4OT3QJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45OjJ{NDFOwG0>	NWXUN4ZRW0GQR1XS
K5 cell	M1n3emdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NYLoWolmUW6qaXLpeIlwdiCxZjDoeY1idiCNNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuNFE3OjRizszN	MnjLV2FPT0WU
MLMA cell	MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MYrJcohq[mm2aX;uJI9nKGi3bXHuJGtQW0NvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuNFMzOTdizszN	NFrWe4VUSU6JRWK=
MLMA cell	MnjKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NH7GdIpKdmirYnn0bY9vKG:oIHj1cYFvKE2OTVGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlI5PzB\|IN88US=>	MoDNV2FPT0WU
EW-7 cell	M17ONmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGVYNTdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkOyOlk2KM7:TR?=	MXfTRW5ITVJ?
SW1088 cell	NWHOdWtoT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MYLJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTB6ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuPFA3PTFizszN	M3rJUXNCVkeHUh?=
MC-IXC cell	MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MVfJcohq[mm2aX;uJI9nKGi3bXHuJG1ENUm[QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuPFc4QTJizszN	MlL4V2FPT0WU
NCI-H2052 cell	Mm[yS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MWXJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkC1NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvODhzNUeg{txO	NFS1ZldUSU6JRWK=
IGR-1 cell	MnyzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NG[yeJNKdmirYnn0bY9vKG:oIHj1cYFvKEmJUj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4yOjB{ODFOwG0>	M{H3NHNCVkeHUh?=
DSH1 cell	NXfadmJDT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MVLJcohq[mm2aX;uJI9nKGi3bXHuJGRUUDFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1\|LkK0Nlk3KM7:TR?=	M4Lwb3NCVkeHUh?=
PA-1 cell	Ml7HS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	Mnm5TY5pcWKrdHnvckBw\iCqdX3hckBRSS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mz6zNFA2Qc7:TR?=	M3viO3NCVkeHUh?=
SK-MEL-3 cell	MkjIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NE\VWJBKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5\|MUKwO{DPxE1?	NUOzW49EW0GQR1XS
SW900 cell	NWHpZ\|hZT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MYXJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTByIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mz60PFI2PSEQvF2=	Mli4V2FPT0WU
CAKI-1 cell	NVPyZpdZT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	M121fmlvcGmkaYTpc44hd2ZiaIXtZY4hS0GNST2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{42Ojd\|ODFOwG0>	NX7PR2lqW0GQR1XS
ES1 cell	NUHhXWg{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	Moq4TY5pcWKrdHnvckBw\iCqdX3hckBGWzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1\|LkWyPFk4KM7:TR?=	NYnDZ\|Q2W0GQR1XS
SK-N-DZ cell	NXjJfY9XT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NXHKfGluUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3OMWRbKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy54MkW5OUDPxE1?	M325NXNCVkeHUh?=
RH-1 cell	NUSwcG5QT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NGfQcYRKdmirYnn0bY9vKG:oIHj1cYFvKFKKLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlY5PDZ\|IN88US=>	NEe3V2RUSU6JRWK=
ES8 cell	MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NUPUWJFnUW6qaXLpeIlwdiCxZjDoeY1idiCHU{igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlY6PzB{IN88US=>	MkO0V2FPT0WU
NEC8 cell	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MWfJcohq[mm2aX;uJI9nKGi3bXHuJG5GSzhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1\|Lke2PVgzKM7:TR?=	NGHtPGFUSU6JRWK=
LNCaP-Clone-FGC cell	M{PENGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M3Pqc2lvcGmkaYTpc44hd2ZiaIXtZY4hVE6FYWCtR4xwdmVvRlfDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{45OzV\|NjFOwG0>	MWfTRW5ITVJ?
HCE-4 cell	NIS2[WxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NULyNnMxUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1WtOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQThyNzFOwG0>	NFTtZ5ZUSU6JRWK=
U-118-MG cell	MnLrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MVjJcohq[mm2aX;uJI9nKGi3bXHuJHUuOTF6LV3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4xOTB4NjFOwG0>	M3v1fnNCVkeHUh?=
GI-ME-N cell	M{jEe2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	Mom4TY5pcWKrdHnvckBw\iCqdX3hckBIUS2PRT3OJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4xQDd7NjFOwG0>	NIfCVVZUSU6JRWK=
LB1047-RCC cell	MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M{DYVGlvcGmkaYTpc44hd2ZiaIXtZY4hVEJzMES3MXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTRwMU[xOFMh\|ryP	Mn\kV2FPT0WU
HT-1080 cell	M1;LN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M1SwWGlvcGmkaYTpc44hd2ZiaIXtZY4hUFRvMUC4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvOTl7MkGg{txO	MofoV2FPT0WU
NB69 cell	NFztW3dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MXPJcohq[mm2aX;uJI9nKGi3bXHuJG5DPjliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkO1NFQ4KM7:TR?=	M1fSUHNCVkeHUh?=
NCI-H1693 cell	MoLuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NF;pNXRKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVY6OyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTRwNES4PVUh\|ryP	M2C4VHNCVkeHUh?=
HSC-3 cell	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MYPJcohq[mm2aX;uJI9nKGi3bXHuJGhUSy1\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND60PVk{OyEQvF2=	NGiyNIZUSU6JRWK=
MDA-MB-231 cell	MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MlzNTY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNlMyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC53NUi5PUDPxE1?	NHHHWFhUSU6JRWK=
HOS cell	NXz4WJkyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NFzmUFdKdmirYnn0bY9vKG:oIHj1cYFvKEiRUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuO\|g3OyEQvF2=	NH;I[m5USU6JRWK=
BT-549 cell	NUjXcpFDT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NWS1cmw4UW6qaXLpeIlwdiCxZjDoeY1idiCEVD21OFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njd6OEeg{txO	M{HucHNCVkeHUh?=
NB17 cell	NVTMTos2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NVHpd4QyUW6qaXLpeIlwdiCxZjDoeY1idiCQQkG3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE44QDl5NjFOwG0>	MlzPV2FPT0WU
5637 cell	M3rEbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	Ml3XTY5pcWKrdHnvckBw\iCqdX3hckA2PjN5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND63PVY2OiEQvF2=	Mne5V2FPT0WU
OVCAR-8 cell	MoS5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MULJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlkzPDN4IN88US=>	NIDVZXZUSU6JRWK=
G-402 cell	NEHMfm1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NVHETFRpUW6qaXLpeIlwdiCxZjDoeY1idiCJLUSwNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQTNyM{Wg{txO	MW\TRW5ITVJ?
BB30-HNC cell	MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MlLDTY5pcWKrdHnvckBw\iCqdX3hckBDSjNyLVjOR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvODd{MUig{txO	MUfTRW5ITVJ?
HCC1806 cell	MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M{LidmlvcGmkaYTpc44hd2ZiaIXtZY4hUEOFMUiwOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvODh\|M{mg{txO	MXLTRW5ITVJ?
COLO-800 cell	MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MUHJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vOECwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4yOjZ2IN88US=>	NUGwU2NSW0GQR1XS
FADU cell	M4P4cGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	Mki1TY5pcWKrdHnvckBw\iCqdX3hckBHSUSXIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NT6zOlU2PyEQvF2=	MkXsV2FPT0WU
NCI-H1651 cell	NYDCRpNTT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NHG1XodKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVY2OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTVwM{m0NFkh\|ryP	M{L6bXNCVkeHUh?=
AGS cell	MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MVnJcohq[mm2aX;uJI9nKGi3bXHuJGFIWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTVwNEe3NVEh\|ryP	NFT3WI1USU6JRWK=
CHP-212 cell	NGLHc\|ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	M3z4SGlvcGmkaYTpc44hd2ZiaIXtZY4hS0iSLUKxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvOzl2MEmg{txO	M16wN3NCVkeHUh?=
YAPC cell	NIXXXZFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NU\Xc5FIUW6qaXLpeIlwdiCxZjDoeY1idiC\QWDDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU41PzdzMTFOwG0>	NXrSU\|Y4W0GQR1XS
GOTO cell	M3fsRWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NGLhfnlKdmirYnn0bY9vKG:oIHj1cYFvKEeRVF:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlQ6PTd4IN88US=>	MYPTRW5ITVJ?
KYSE-510 cell	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M1yzcWlvcGmkaYTpc44hd2ZiaIXtZY4hU1mVRT21NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjVzMTFOwG0>	M4mwOXNCVkeHUh?=
NCI-H2342 cell	MnexS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	MYTJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkO0NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPTN{N{ig{txO	M2juT3NCVkeHUh?=
BFTC-905 cell	M4rsOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MnjMTY5pcWKrdHnvckBw\iCqdX3hckBDTlSFLUmwOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPjJ6M{Wg{txO	MUjTRW5ITVJ?
EW-16 cell	NUTMUIFYT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NFLIb\|VKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU44OjB7MzFOwG0>	MmPjV2FPT0WU
SK-MEL-30 cell	MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MVHJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD2zNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPzR3NEOg{txO	MonDV2FPT0WU
HLE cell	NED4NVVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	NX\vNWc2UW6qaXLpeIlwdiCxZjDoeY1idiCKTFWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlc4PDh7IN88US=>	M2HENXNCVkeHUh?=
T98G cell	NWXqcnZYT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NEjBe2tKdmirYnn0bY9vKG:oIHj1cYFvKFR7OFegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlc6PjN3IN88US=>	NHvIcYNUSU6JRWK=
HUTU-80 cell	NUPMWFR1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NF24S3NKdmirYnn0bY9vKG:oIHj1cYFvKEiXVGWtPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Njh2MkK4JO69VQ>?	NIDQdG1USU6JRWK=
NOS-1 cell	Mn\RS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	NV74bG5bUW6qaXLpeIlwdiCxZjDoeY1idiCQT2OtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQTR5Nk[g{txO	MoPNV2FPT0WU
SW780 cell	M3jqdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NV;6eHMzUW6qaXLpeIlwdiCxZjDoeY1idiCVV{e4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQTZ7NEmg{txO	NH25V4pUSU6JRWK=
KYSE-180 cell	NYfmS2VJT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NV3H[XFEUW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVE5OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTVwOUe2OVQh\|ryP	MorpV2FPT0WU
MDA-MB-361 cell	NEfyR2VIem:5dHigbY5pcWKrdHnvckBie3OjeR?=	MlG4TY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtN\|YyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS57OE[0O{DPxE1?	NFfzfpRUSU6JRWK=
SNU-C2B cell	M3PNXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7	MkPJTY5pcWKrdHnvckBw\iCqdX3hckBUVlVvQ{LCJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Ok4xOTF\|ODFOwG0>	M4L4XnNCVkeHUh?=
NCI-H661 cell	MnrKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M3vEN2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi2OlEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjB4OUSg{txO	NVrPUohiW0GQR1XS
OE33 cell	M33xe2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	M3KwemlvcGmkaYTpc44hd2ZiaIXtZY4hV0V\|MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPU[uNVQ{QDlizszN	MVPTRW5ITVJ?
TYK-nu cell	MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	NYXQbZhDUW6qaXLpeIlwdiCxZjDoeY1idiCWWVutcpUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjJzOE[zJO69VQ>?	MW\TRW5ITVJ?
COLO-792 cell	NXjiOWl6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MmK3TY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLUe5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvOjV{MUmg{txO	NX7VOnR1W0GQR1XS
HEL cell	M{Djb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7	NG\yXoJKdmirYnn0bY9vKG:oIHj1cYFvKEiHTDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPU[uNlY4PiEQvF2=	NH\HPYVUSU6JRWK=
D-566MG cell	NUPGTGlST3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NGi4cWdKdmirYnn0bY9vKG:oIHj1cYFvKERvNU[2UWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjN\|NEmxJO69VQ>?	M3vDRnNCVkeHUh?=
U031 cell	NWTafWV7T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	NF7ycGVKdmirYnn0bY9vKG:oIHj1cYFvKFVyM{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlQyQDF4IN88US=>	NV;3T\|dqW0GQR1XS
COR-L23 cell	MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MXXJcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlQ{OzR4IN88US=>	NIeyOm5USU6JRWK=
NCI-H2452 cell	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	MVvJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkS1NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPTJ{OEGg{txO	M3XKcnNCVkeHUh?=
BB65-RCC cell	MlT0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?	M3XzemlvcGmkaYTpc44hd2ZiaIXtZY4hSkJ4NT3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjZ2NUmg{txO	MUDTRW5ITVJ?
CAL-33 cell	NXj1dWY{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=	MWTJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC1\|MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPU[uOlU3PjVizszN	NFvOW4xUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p53 / HDM2 / HDMX / p21 / Noxa / Puma ; PubMed: 20736344 Mol Cancer Ther OCI-AML-3 and MOLM-13 cells were incubated with a range of concentrations of JNJ-26854165 for 18 hours. ABCA1 / ABCG1 / NPC1 / NPC2 / HMGcoR ; PubMed: 23820125 J Pharmacol Exp Ther U266 and JeKo-1 cells were treated with JNJ-26854165 and cells harvested at the indicated time points. MDM2 / p-MDM2 / p53 ; PubMed: 27999193 Oncotarget K562 cells was harvested at 48 h after treatment with various JNJ-165 concentrations, and then nuclear and cytoplasmic extracts were prepared to check the levels of p53, MDM2 and p-MDM2 by Western blotting. Actin and LaminB were used as loading control respectively. Bcr-abl / p-Bcr-abl / p-CrkL / STAT5 / p-STAT5 / STAT3 / p-STAT3 ; PubMed: 27999193 Oncotarget CML cell lines were treated with JNJ-165 at the indicated doses for 48 h. Whole-cell lysates were extracted to assess the levels of BCR-ABL and phosphorylated (p)-BCR-ABL (Tyr177), and then were analyzed for BCR-ABL downstream signaling mediators p-CrkL (Try207), total Stat5, p-Stat5 (Tyr694), total Stat3, and p-Stat3 (Ser727) expression by Western blot analysis. The expression of β-actin was used as loading control. The data are representative of three determinations with identical results.	20736344 23820125 27999193
Growth inhibition assay	Cell viability; PubMed: 23820125 J Pharmacol Exp Ther MCL (B) and MM (C) cell lines were seeded in 96-well plates for viability analyses using WST-1 and treated with JNJ-26854165 for 72 hours. Results are expressed as the percentage of cell viability in relation to the vehicle-treated sample for each cell line, which was arbitrarily set at 100%	23820125
Immunofluorescence	p53; PubMed: 27999193 Oncotarget Two-color fluorescence microscope analysis of antibody against p53 protein (green) and nuclei (DAPI staining, blue) showed nuclear accumulation of p53 in K562 cells with treatment of 1 μM JNJ-165, but not in control-treated cells after 48 h. Images were taken on a fluorescence microscopy (100×).	27999193

In vivo

JNJ 26854165 leads to significant differences in EFS distribution in 17 of the 36 (47%) evaluable solid tumor xenografts and in 5 of 7 (71%) of the evaluable ALL xenografts using a dose of 20 mg/kg administered via oral gavage daily for 5 days, repeated for 6 weeks. ^[4]

Protocol

Cell Research:^[1]

- Collapse

Cell lines: OCI-AML-3, MOLM-13, NB4 and U937 cells
Concentrations: 0-10 μM
Incubation Time: 72 hours
Method: Cell lines are maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS). OCI-AML-3, MOLM-13, NB4 and U937 cells are derived from acute myelogenous leukemia (AML) patients, K562 from a chronic myelogenous leukemia (CML) patient in blast crisis, and NALM-6, REH, P12-ICHIK
(Only for Reference)

Animal Research:^[4]

- Collapse

Animal Models: CB17SC scid^-/- female mice.
Dosages: ≤20 mg/kg
Administration: Administered via p.o.
(Only for Reference)

References

[4] Smith MA, et al. Pediatr Blood Cancer, 2012, 59(2), 329-332.

- Collapse

Solubility (25°C)

In vitro	DMSO	66 mg/mL (200.96 mM)
	Water	Insoluble
	Ethanol	'2 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% DMSO+30% polyethylene glycol+1% Tween 80 For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Serdemetan (JNJ-26854165) SDF

Molecular Weight	328.41
Formula	C₂₁H₂₀N₄
CAS No.	881202-45-5
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	C1=CC=C2C(=C1)C(=CN2)CCNC3=CC=C(C=C3)NC4=CC=NC=C4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00676910	Completed	Drug: JNJ-26854165	Neoplasms	Johnson & Johnson Pharmaceutical Research & Development L.L.C.	November 2006	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

p53 Signaling Pathway Map

Related p53 Products

MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
RITA (NSC 652287)

RITA (NSC 652287) induces both DNA-protein and DNA-DNA cross-links with no detectable DNA single-strand breaks, and also inhibits MDM2-p53 interaction by targeting p53.

Features:Inducer of DNA cross-links, not a DNA intercalator.
Pifithrin-α (PFTα) HBr

Pifithrin-α is an inhibitor of p53, inhibiting p53-dependent transactivation of p53-responsive genes. Pifithrin-α is also a potent agonist of the aryl hydrocarbon receptor (AhR).
Tenovin-1

Tenovin-1 protects against MDM2-mediated p53 degradation, which involves ubiquitination, and acts through inhibition of protein-deacetylating activities of SirT1 and SirT2. Tenovin-1 is also an inhibitor of dihydroorotate dehydrogenase (DHODH).
Tenovin-6

Tenovin-6 is a small molecule activator of p53 transcriptional activity and inhibits dihydroorotate dehydrogenase (DHODH). Tenovin-6 is also an inhibitor of SirT1 and SirT2.
Pifithrin-μ

Pifithrin-μ (NSC 303580, PFTμ, 2-Phenylethynesulfonamide) is a specific p53 inhibitor by reducing its affinity to Bcl-xL and Bcl-2, and also inhibits HSP70 function and autophagy.
Z-VAD-FMK

Z-VAD-FMK (Z-VAD(OMe)-FMK) is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

Features:A key compound for apoptosis studies.

Choose Your Country or Region

By Signaling Pathways

By product type

Serdemetan (JNJ-26854165)